Anna C. Zemke

Jun 22, 2024 | onlinelibrary.wiley.com | Christine Liu |Jonathan B. Overdevest |Anna C. Zemke |Jess C. Mace

No abstract is available for this article. BIBLIOGRAPHY 1, , , et al. Predictors of sinonasal improvement after highly effective modulator therapy in adults with cystic fibrosis. Laryngoscope. 2024. https://doi.org/10.1002/lary.31438. 2, , , et al. Elexacaftor-tezacaftor-ivacaftor improves sinonasal outcomes in cystic fibrosis. J Cyst Fibros. 2022; 21(5): 792-799. https://doi.org/10.1016/j.jcf.2022.03.002. 3, , , et al.

Apr 18, 2024 | onlinelibrary.wiley.com | Daniel Beswick |Christine Liu |Jonathan B. Overdevest |Anna C. Zemke

INTRODUCTION Chronic rhinosinusitis (CRS) is prevalent in people with cystic fibrosis (PwCF).1-3 CRS in PwCF is associated with diminished quality of life (QOL), olfactory dysfunction, worse lower airway health, and increased treatment burden.4-6 Management approaches for CF-CRS are shifting with the introduction of highly effective CF transmembrane conductance regulator (CFTR) modulator therapy (HEMT), such as elexacaftor/tezacaftor/ivacaftor (ETI), which cause marked improvement in a wide...